Categorized | Scientific Publications

Melanoma Journal Articles for October 2018

Cancer Epidemiology, Biomarkers and Prevention

Reviews

An Epidemiological Review of Diet and Cutaneous Malignant Melanoma

Keming Yang, Teresa T. Fung and Hongmei Nan

DOI: 10.1158/1055-9965.EPI-18-0243 Published October 2018


BMJ

Cancer genetics

Short report

Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations

Hildur Helgadottir, Paola Ghiorzo, Remco van Doorn, Susana Puig, Max Levin, Richard Kefford, Martin Lauss, Paola Queirolo, Lorenza Pastorino, Ellen Kapiteijn, Miriam Potrony, Cristina Carrera, Håkan Olsson, Veronica Höiom, Göran Jönsson

http://dx.doi.org/10.1136/jmedgenet-2018-105610


JAMA Dermatology

Original Investigation

October 10, 2018

Risk of Subsequent Cutaneous Melanoma in Moderately Dysplastic Nevi Excisionally Biopsied but With Positive Histologic Margins Caroline C. Kim, MD1; Elizabeth G. Berry, MD2,3; Michael A. Marchetti, MD4; et alSusan M. Swetter, MD5,6; Geoffrey Lim, MD7; Douglas Grossman, MD, PhD8,9; Clara Curiel-Lewandrowski, MD10; Emily Y. Chu, MD, PhD11; Michael E. Ming, MD, MSCE11; Kathleen Zhu, BA12; Meera Brahmbhatt, MD2,13; Vijay Balakrishnan, BS2,3; Michael J. Davis, BMus2,3; Zachary Wolner, BA4; Nathaniel Fleming, BA5,6; Laura K. Ferris, MD, PhD7; John Nguyen, BA14; Oleksandr Trofymenko, BA10; Yuan Liu, PhD2; Suephy C. Chen, MD, MS2,3; for the Pigmented Lesion Subcommittee, Melanoma Prevention Working Group

JAMA Dermatol. Published online October 10, 2018. doi:10.1001/jamadermatol.2018.3359


ACTA DERMATO VENEREOLOGICA

Induced Vitiligo due to Talimogene Laherparepvec Injection for Metastatic Melanoma Associated with Long-term Complete Response

Pablo Iglesias, Simone Ribero, Alicia Barreiro, Sebastian Podlipnik, Cristina Carrera, Josep Malvehy, Susana Puig DOI: 10.2340/00015555-3061


ACTA DERMATO VENEREOLOGICA

Paraneoplastic Opsoclonus-Myoclonus Syndrome Preceding a Mucosal Malignant Melanoma

Flora Dresco, François Aubin, Elise Deveza, Eugeniu Revenco, Laurent Tavernier, Eve Puzenat DOI: 10.2340/00015555-3062


Dove Press

Biomimetic quantum dot-labeled B16F10 murine melanoma cells as a tool to monitor early steps of lung metastasis by in vivo imaging Authors Díaz-García VM, Guerrero S, Díaz-Valdivia N, Lobos-González L, Kogan M, Pérez-Donoso JM, Quest AFG

Received 15 February 2018

Accepted for publication 30 May 2018

Published 16 October 2018 Volume 2018:13 Pages 6391—6412 DOI https://doi.org/10.2147/IJN.S165565


Dove Press

Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma

Authors Kakadia S, Yarlagadda N, Awad R, Kundranda M, Niu J, Naraev B, Mina L, Dragovich T, Gimbel M, Mahmoud F

Received 5 August 2018

Accepted for publication 19 September 2018

Published 17 October 2018 Volume 2018:11 Pages 7095—7107 DOI https://doi.org/10.2147/OTT.S182721


Clinical Cancer Research

Bigger Is Not Always Better: Tumor Size and Prognosis in Advanced Melanoma

Allison Betof Warner and Michael A. Postow

DOI: 10.1158/1078-0432.CCR-18-1311 Published October 2018


The Lancet

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial Frank Stephen Hodi, MD ,Vanna Chiarion-Sileni, MD, Prof Rene Gonzalez, MD, Prof Jean-Jacques Grob, MD, Prof Piotr Rutkowski, MD, Charles Lance Cowey, MD, et al. Published:October 22, 2018DOI:https://doi.org/10.1016/S1470-2045(18)30700-9


Journal of Investigative Dermatology

Association between phenotypic characteristics and melanoma in a large prospective cohort study Catherine M. Olsen, Nirmala Pandeya, Bridie S. Thompson, Jean Claude Dusingize, Adele C. Green, Rachel E. Neale, David C. Whiteman

for the QSkin Study DOI: https://doi.org/10.1016/j.jid.2018.09.022


JAMA Dermatology

Observation

October 24, 2018

Herpetic Whitlow—A Case of Inadvertent Inoculation With Melanoma Viral Therapy Jonathan M. Soh, MD1; Eva Galka, MD2; Mary Gail Mercurio, MD1

Author Affiliations

JAMA Dermatol. Published online October 24, 2018. doi:10.1001/jamadermatol.2018.3584


Dove Press

The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis

Authors Li P, Yang X, Feng Y, Wu L, Ma W, Ding G, Wei Y, Sun L

Received 12 February 2018

Accepted for publication 13 May 2018

Published 26 October 2018 Volume 2018:11 Pages 7521—7527 DOI https://doi.org/10.2147/OTT.S165368


Molecular Cancer Research

Signal Transduction

miR-122-5p Expression and Secretion in Melanoma Cells Is Amplified By the LPAR3 SH3–Binding Domain to Regulate Wnt1

Charnel C. Byrnes, Wei Jia, Ali A. Alshamrani, Sudeepti S. Kuppa and Mandi M. Murph

DOI: 10.1158/1541-7786.MCR-18-0460


Molecules 2018, 23(11), 2820; https://doi.org/10.3390/molecules23112820

Synthesis of Novel Shikonin Derivatives and Pharmacological Effects of Cyclopropylacetylshikonin on Melanoma Cells

Christin Durchschein, Antje Hufner, Beate Rinner, Alexander Stallinger, Alexander Deutsch, Birgit Lohberger, Rudolf Bauer and Nadine Kretschmer

Received: 9 October 2018 / Revised: 19 October 2018 / Accepted: 20 October 2018 / Published: 30 October 2018


International Journal of Cancer

Cancer Epidemiology

Oral contraceptive use and cutaneous melanoma risk: a French prospective cohort study I. Cervenka Y. Mahamat?Saleh I. Savoye L. Dartois M.C. Boutron?Ruault A. Fournier M. Kvaskoff

First published: 06 July 2018 https://doi.org/10.1002/ijc.31644


International Journal of Cancer

Cancer Therapy and Prevention

Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma Bin Zhao Hong Zhao Jiaxin Zhao

First published: 19 August 2018 https://doi.org/10.1002/ijc.31813


JAMA

Original Investigation

October 2018

Association of Uveal Melanoma Metastatic Rate With Stochastic Mutation Rate and Type of Mutation Eszter Szalai, MD, PhD1,2; Yi Jiang, PhD3; Natasha M. van Poppelen, MD4,5; et alMartine J. Jager, MD, PhD6; Annelies de Klein, PhD5; Emine Kilic, MD, PhD4; Hans E. Grossniklaus, MD1,7

JAMA Ophthalmol. 2018;136(10):1115-1120. doi:10.1001/jamaophthalmol.2018.2986


JAMA

Original Investigation

October 2018

Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600–Mutated Metastatic MelanomaPooled Analysis of 4 Randomized Clinical Trials Axel Hauschild, MD1; James Larkin, FRCP2; Antoni Ribas, MD3; et alBrigitte Dréno, MD4; Keith T. Flaherty, MD5; Paolo A. Ascierto, MD6; Karl D. Lewis, MD7; Edward McKenna, PharmD8; Qian Zhu, PhD8; Yong Mun, PhD8; Grant A. McArthur, FRACP9,10

JAMA Oncol. 2018;4(10):1382-1388. doi:10.1001/jamaoncol.2018.2668


Journal of Clinical Oncology

ORIGINAL REPORTS

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma Diwakar Davar, Hong Wang, Joe-Marc Chauvin, Ornella Pagliano, Julien J. Fourcade, Mignane Ka, Carmine Menna, Amy Rose, Cindy Sander, Amir A. Borhani, Arivarasan Karunamurthy, Ahmad A. Tarhini, Hussein A. Tawbi, Qing Zhao, Blanca H. Moreno, Scott Ebbinghaus, Nageatte Ibrahim, John M. Kirkwood, and Hassane M. Zarour

DOI: 10.1200/JCO.18.00632 Journal of Clinical Oncology – published online before print October 25, 2018